Vimarsana
Biggest News Aggregation in the World

Page 2 - Recurrence Risk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recurrence Risk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recurrence Risk Today - Breaking & Trending Today

Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence - Vimarsana News

Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Strong Analytical Validation Data Further Supports Use of DCISionRT® to Guide Shared Decision-Making for DCIS Therapeutic Management - Vimarsana News

Strong Analytical Validation Data Further Supports Use of DCISionRT® to Guide Shared Decision-Making for DCIS Therapeutic Management

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that...

Guardant Health Files Lawsuit Against Natera for Misleading Oncologists - Vimarsana News

Guardant Health Files Lawsuit Against Natera for Misleading Oncologists

Posted on 465 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today filed a lawsuit against Natera, Inc. for false advertising, unfair competition, and unlawful trade practices, relating to misleading statements Natera has made about its own products and the performance of Guardant Health’s new oncology test, Guardant Reveal™. Guardant Health asked the federal court in San Francisco, California for an injunction preventing Natera from continuing to make these false or misleading statements and requirin...